ICVTS Click here to goto Smart Canula website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Phil Botha
Joel Dunning
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagarajan, D. V.
Right arrow Articles by Dunning, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagarajan, D. V.
Right arrow Articles by Dunning, J.
Related Collections
Right arrow Cardiac - pharmacology
Right arrow Cardiac - other
Right arrow Education
Interactive Cardiovascular and Thoracic Surgery 3:450-455(2004)
© 2004 European Association of Cardio-Thoracic Surgery

Best evidence topic - Cardiac general

Is addition of anti-platelet therapy to warfarin beneficial to patients with prosthetic heart valves?

Darbhamulla V. Nagarajana, Philip S. Lewisa, Phil Bothab and Joel Dunningb,*

a Department of Cardiology, Stepping Hill Hospital, Stockport, Manchester, UK
b Department of Cardiothoracic Surgery, Freeman Hospital, Freeman Road, NE7 7DN, Newcastle upon Tyne, UK

* Corresponding author. Address: Department of Cardiothoracic Surgery, Freeman Hospital, Freeman Road, NE7 7DN, Newcastle upon Tyne, UK
joeldunning{at}doctors.org.uk

A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether addition of anti-platelet therapy to warfarin reduced the incidence of thromboembolic complications in patients with prosthetic heart valves. Altogether 253 papers were found using the reported search, of which 11 papers represented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results, and study weaknesses were tabulated. We conclude that low dose aspirin (80–100 mg daily) in addition to warfarin in patients with prosthetic heart valves reduces all cause long term mortality (NNT=19), with significant reductions in thromboembolism but an increase in bleeding.

Key Words: Evidence-based medicine; Prosthetic heart valves; Antiplatelet therapy; Warfarin; Review; Thoracic surgery




This article has been cited by other articles:


Home page
 Card Surg AdultHome page
Z. I. Khalpey, R. B. Ganim, and J. D. Rawn
Postoperative Care of Cardiac Surgery Patients
Card. Surg. Adult, January 1, 2008; 3(2008): 465 - 486.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 European Association for Cardio-thoracic Surgery